What does this research mean for the field?

Etiology and treatment response are the dominant independent predictors of favorable developmental outcomes at 3 years of age in children with infantile epileptic spasms syndrome. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate three-year developmental outcomes and determine independent predictors of favorable development in children with infantile epileptic spasms syndrome treated with a standardized stepwise protocol of vigabatrin and high-dose prednisolone.

September 14, 2026Epilepsia OpenOpen Access

Long‐term developmental outcome in infantile epileptic spasms syndrome after high‐dose prednisolone and vigabatrin treatment

View Full Paper

Ask AI

Bookmark

Authors

SJSoyoung Jang HSHui Jin Shin SKSe Hee Kim

Discussion

Member takes

Overview

Prospective cohort study reveals that etiology and treatment response drive three-year developmental outcomes in infantile epileptic spasms syndrome, highlighting the need for tailored therapy.

Key Points

To evaluate three-year developmental outcomes and determine independent predictors of favorable development in children with infantile epileptic spasms syndrome treated with a standardized stepwise protocol of vigabatrin and high-dose prednisolone.
Prospective single-center cohort study of 236 children with infantile epileptic spasms syndrome managed with initial vigabatrin and add-on high-dose oral prednisolone for nonresponders between March 2016 and April 2022 at Severance Children's Hospital.
Developmental outcome at 3 years was categorized as favorable (mental quotient ≥ 70 and psychomotor quotient ≥ 70) or unfavorable using the Bayley Scales of Infant and Toddler Development, Second Edition, with multivariable logistic regression via Firth's penalized method.
Overall treatment response occurred in 175 of 236 patients (74.2%), and 49 patients (20.8%) reached a favorable developmental outcome at 3 years.
Multivariable analysis showed structural etiology (aOR 0.085; 95% CI 0.026–0.281; p < 0.001), genetic etiology (aOR 0.023; 95% CI 0.002–0.357; p = 0.007), and treatment unresponsiveness (aOR 0.030; 95% CI 0.002–0.523; p = 0.02) independently decreased the odds of favorable development.
Zero of 49 patients with a confirmed genetic etiology and zero of 61 unresponsive patients achieved a favorable developmental outcome.

Cite This Study

Jang et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3df0926e14a848b332b https://doi.org/10.1002/epi4.70319

View Full Paper

Ask AI

Bookmark

September 14, 2026Epilepsia OpenOpen Access

Long‐term developmental outcome in infantile epileptic spasms syndrome after high‐dose prednisolone and vigabatrin treatment

View Full Paper

Ask AI

Bookmark

Authors

SJSoyoung Jang HSHui Jin Shin SKSe Hee Kim

Discussion

Member takes

Overview

Prospective cohort study reveals that etiology and treatment response drive three-year developmental outcomes in infantile epileptic spasms syndrome, highlighting the need for tailored therapy.

Key Points

To evaluate three-year developmental outcomes and determine independent predictors of favorable development in children with infantile epileptic spasms syndrome treated with a standardized stepwise protocol of vigabatrin and high-dose prednisolone.
Prospective single-center cohort study of 236 children with infantile epileptic spasms syndrome managed with initial vigabatrin and add-on high-dose oral prednisolone for nonresponders between March 2016 and April 2022 at Severance Children's Hospital.
Developmental outcome at 3 years was categorized as favorable (mental quotient ≥ 70 and psychomotor quotient ≥ 70) or unfavorable using the Bayley Scales of Infant and Toddler Development, Second Edition, with multivariable logistic regression via Firth's penalized method.
Overall treatment response occurred in 175 of 236 patients (74.2%), and 49 patients (20.8%) reached a favorable developmental outcome at 3 years.
Multivariable analysis showed structural etiology (aOR 0.085; 95% CI 0.026–0.281; p < 0.001), genetic etiology (aOR 0.023; 95% CI 0.002–0.357; p = 0.007), and treatment unresponsiveness (aOR 0.030; 95% CI 0.002–0.523; p = 0.02) independently decreased the odds of favorable development.
Zero of 49 patients with a confirmed genetic etiology and zero of 61 unresponsive patients achieved a favorable developmental outcome.

Cite This Study

Jang et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3df0926e14a848b332b https://doi.org/10.1002/epi4.70319

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark